Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3
| Autor: | Norbert Arnold, Sabine Adam-Klages, Regina Fredrik, Christel Eckmann-Scholz, Amke Caliebe, Susanne Sebens, Jörg Weimer, Yaxi Ma, Christian Schem, Felix Hilpert |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
medicine.medical_specialty
endocrine system diseases Aurora inhibitor Antineoplastic Agents Apoptosis Biology Carboplatin Polyploidy Chromosome segregation Cell Line Tumor Internal medicine Ovarian carcinoma medicine Aurora Kinase B Humans Cell Proliferation Caspase 7 Ovarian Neoplasms Caspase 3 Carcinoma Obstetrics and Gynecology Drug Synergism Cell Cycle Checkpoints General Medicine Cell cycle Organophosphates Endocrinology Cell culture Quinazolines Cancer research Female Cisplatin Ploidy |
| Zdroj: | Archives of Gynecology and Obstetrics. 288:173-182 |
| ISSN: | 1432-0711 0932-0067 |
| Popis: | The treatment of ovarian tumors is carried out with platinum medicine which can lead to incompatibilities or resistances. Thus, it is of great interest to check new medicine suitability for its application. AZD1152 is an Aurora kinase inhibitor predominantly works against Aurora kinase B involved in the chromosome segregation. Cells become polyploidy and reduce the proliferation by this impairment. To investigate whether AZD1152, may play a role in the treatment of ovarian carcinoma we serving it to the cisplatinum-resistant cell line SKOV3 alone and in combination with platinum. We look at the proliferation, the ploidy, the phases of cell cycle and the apoptosis activity of the cells. We could show that the combination of both medicines in the preclinical experiment produces a working advantage. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink